Andre Goy
Chairman and Executive Director, John Theurer Cancer Center
Hackensack Meridian Health · Hackensack, United States
Led key trials establishing lenalidomide as a treatment option in relapsed MCL. Chairs one of the leading cancer centers on the East Coast.
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.
Blood · Mar 19, 2026
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.
Nature communications · Nov 5, 2025
Updates on the Biological Heterogeneity of Mantle Cell Lymphoma.
Cancers · Feb 19, 2025
SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024.
Clinical lymphoma, myeloma & leukemia · Aug 1, 2024
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Haematologica · Jan 1, 2024